“INTERCEPT has a unique and highly international character bringing together bright scientists from across the European continent, North America and South Korea. This creates numerous opportunities and the potential to lead to the most significant scientific progress in the field since the initial description of the disease by Burrill Crohn himself in 1932.”

“For the first time, researchers from multiple European countries, North America and South Korea are working together to predict and prevent Crohn’s Disease, reaching a milestone in the long path we began to walk many years ago. Our combined success would reinforce the concept that immune-mediated diseases that not only affect the gut but also the joints, the skin and the brain can be prevented.”

“At Takeda, we are committed to improving outcomes for people living with Crohn’s disease and have been working together with leaders across the IBD landscape for more than thirty-five years towards this goal. We know that addressing the complexities of Crohn’s disease is only possible through deep engagement of the industry with the broader scientific community, and our partnership with the Innovative Health Initiative reflects this. Our great hope is that the INTERCEPT Project helps to develop and deploy a biomarker panel that ultimately enables effective and early diagnosis and treatment of Crohn’s disease, even before symptoms begin, thus changing the course of disease and lessening the immense burden of this chronic illness on patients and their loved ones.”